PRECISION BIOSCIENCES INC
For the period ended Nov 5, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 5, 2026 · Filed Nov 5, 2026
Contents
EX-99.3 · About FUNCTION-DMD Trial
About FUNCTION-DMD Trial
The Phase 1/2 FUNCTION-DMD study is enrolling ambulatory DMD patients between the ages of 2 and 7 with mutations between exons 45 and 55 representing up to 60% of boys with DMD. The objective of the FUNCTION-DMD study is to evaluate safety, tolerability, and efficacy, including dystrophin protein expression and functional outcomes in patients living with DMD. For more information about this clinical trial and contact information, please visitwww.clinicaltrials.gov and search for NCT07429240.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.